Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Acute and residual effects of smoked cannabis: Impact on driving speed and lateral control, heart rate, and self-reported drug effects.

Brands B, Mann RE, Wickens CM, Sproule B, Stoduto G, Sayer GS, Burston J, Pan JF, Matheson J, Stefan C, George TP, Huestis MA, Rehm J, Le Foll B.

Drug Alcohol Depend. 2019 Oct 18;205:107641. doi: 10.1016/j.drugalcdep.2019.107641. [Epub ahead of print]

PMID:
31678833
2.

Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults.

Matheson J, Sproule B, Di Ciano P, Fares A, Le Foll B, Mann RE, Brands B.

Psychopharmacology (Berl). 2019 Oct 22. doi: 10.1007/s00213-019-05369-y. [Epub ahead of print]

PMID:
31637452
3.

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.

Elsaid S, Kloiber S, Le Foll B.

Prog Mol Biol Transl Sci. 2019;167:25-75. doi: 10.1016/bs.pmbts.2019.06.005. Epub 2019 Aug 28.

PMID:
31601406
4.

Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline.

Fairbairn N, Ross J, Trew M, Meador K, Turnbull J, MacDonald S, Oviedo-Joekes E, Le Foll B, Goyer MÈ, Perreault M, Sutherland C.

CMAJ. 2019 Sep 23;191(38):E1049-E1056. doi: 10.1503/cmaj.190344. No abstract available.

5.

The complexity of pharmacology of cannabidiol (CBD) and its implications in the treatment of brain disorders.

Elsaid S, Le Foll B.

Neuropsychopharmacology. 2019 Sep 11. doi: 10.1038/s41386-019-0518-1. [Epub ahead of print] No abstract available.

PMID:
31511618
6.

The effect of a clinical decision support system on prompting an intervention for risky alcohol use in a primary care smoking cessation program: a cluster randomized trial.

Minian N, Baliunas D, Noormohamed A, Zawertailo L, Giesbrecht N, Hendershot CS, Le Foll B, Rehm J, Samokhvalov AV, Selby PL.

Implement Sci. 2019 Aug 23;14(1):85. doi: 10.1186/s13012-019-0935-x.

7.

Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents.

Nielsen S, Sabioni P, Gowing L, Le Foll B.

Handb Exp Pharmacol. 2019 Aug 3. doi: 10.1007/164_2019_258. [Epub ahead of print]

PMID:
31375922
8.

The Insula: A Brain Stimulation Target for the Treatment of Addiction.

Ibrahim C, Rubin-Kahana DS, Pushparaj A, Musiol M, Blumberger DM, Daskalakis ZJ, Zangen A, Le Foll B.

Front Pharmacol. 2019 Jul 2;10:720. doi: 10.3389/fphar.2019.00720. eCollection 2019. Review.

9.

Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders.

Andrews CN, Devlin SM, Le Foll B, Fischer B, Tse F, Storr M, Congly SE.

J Can Assoc Gastroenterol. 2019 Apr;2(1):37-43. doi: 10.1093/jcag/gwy064. Epub 2018 Nov 8. No abstract available.

10.

The Human Laboratory and Drug Development in Alcohol Use Disorder: Recent Updates.

Chukwueke CC, Le Foll B.

Methods Mol Biol. 2019;2011:195-219. doi: 10.1007/978-1-4939-9554-7_12.

PMID:
31273701
11.
12.

Randomized Clinical Trials Investigating Innovative Interventions for Smoking Cessation in the Last Decade.

Gendy MNS, Ibrahim C, Sloan ME, Le Foll B.

Handb Exp Pharmacol. 2019 Jul 3. doi: 10.1007/164_2019_253. [Epub ahead of print]

PMID:
31267165
13.

Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research.

Nona CN, Hendershot CS, Le Foll B.

Exp Clin Psychopharmacol. 2019 Aug;27(4):359-369. doi: 10.1037/pha0000272. Epub 2019 May 23.

PMID:
31120285
14.

Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review.

Butler K, Le Foll B.

Front Psychiatry. 2019 Mar 1;10:98. doi: 10.3389/fpsyt.2019.00098. eCollection 2019. Review.

15.

Polydrug use disorders in individuals with opioid use disorder.

Hassan AN, Le Foll B.

Drug Alcohol Depend. 2019 May 1;198:28-33. doi: 10.1016/j.drugalcdep.2019.01.031. Epub 2019 Feb 28.

PMID:
30877954
16.

Pharmacotherapies for cannabis dependence.

Nielsen S, Gowing L, Sabioni P, Le Foll B.

Cochrane Database Syst Rev. 2019 Jan 28;1:CD008940. doi: 10.1002/14651858.CD008940.pub3.

PMID:
30687936
17.

Occupancy of dopamine D2 and D3 receptors by a novel D3 partial agonist BP1.4979: a [11C]-(+)-PHNO PET study in humans.

Di Ciano P, Mansouri E, Tong J, Wilson AA, Houle S, Boileau I, Duvauchelle T, Robert P, Schwartz JC, Le Foll B.

Neuropsychopharmacology. 2019 Jun;44(7):1284-1290. doi: 10.1038/s41386-018-0285-4. Epub 2018 Nov 30.

PMID:
30659274
18.

Transcriptomic Characterization of the Human Habenula Highlights Drug Metabolism and the Neuroimmune System.

Le Foll B, French L.

Front Neurosci. 2018 Oct 31;12:742. doi: 10.3389/fnins.2018.00742. eCollection 2018.

19.

Varenicline and Bupropion for Long-Term Smoking Cessation (the MATCH Study): Protocol for a Real-World, Pragmatic, Randomized Controlled Trial.

Zawertailo L, Mansoursadeghi-Gilan T, Zhang H, Hussain S, Le Foll B, Selby P.

JMIR Res Protoc. 2018 Oct 18;7(10):e10826. doi: 10.2196/10826.

20.

Testing the PPAR hypothesis of tobacco use disorder in humans: A randomized trial of the impact of gemfibrozil (a partial PPARα agonist) in smokers.

Gendy MNS, Di Ciano P, Kowalczyk WJ, Barrett SP, George TP, Heishman S, Le Foll B.

PLoS One. 2018 Sep 27;13(9):e0201512. doi: 10.1371/journal.pone.0201512. eCollection 2018.

21.

Endocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies.

Sloan ME, Grant CW, Gowin JL, Ramchandani VA, Le Foll B.

Acta Pharmacol Sin. 2019 Mar;40(3):342-350. doi: 10.1038/s41401-018-0081-z. Epub 2018 Aug 30. Review.

PMID:
30166624
22.

A transdiagnostic dimensional approach towards a neuropsychological assessment for addiction: an international Delphi consensus study.

Yücel M, Oldenhof E, Ahmed SH, Belin D, Billieux J, Bowden-Jones H, Carter A, Chamberlain SR, Clark L, Connor J, Daglish M, Dom G, Dannon P, Duka T, Fernandez-Serrano MJ, Field M, Franken I, Goldstein RZ, Gonzalez R, Goudriaan AE, Grant JE, Gullo MJ, Hester R, Hodgins DC, Le Foll B, Lee RSC, Lingford-Hughes A, Lorenzetti V, Moeller SJ, Munafò MR, Odlaug B, Potenza MN, Segrave R, Sjoerds Z, Solowij N, van den Brink W, van Holst RJ, Voon V, Wiers R, Fontenelle LF, Verdejo-Garcia A.

Addiction. 2019 Jun;114(6):1095-1109. doi: 10.1111/add.14424. Epub 2018 Oct 5.

23.

Understanding the implications of the biobehavioral basis of nicotine addiction and its impact on the efficacy of treatment.

Bozinoff N, Le Foll B.

Expert Rev Respir Med. 2018 Sep;12(9):793-804. doi: 10.1080/17476348.2018.1507736. Epub 2018 Aug 13. Review.

PMID:
30092681
24.

Thinking Beyond Legalization: The Case for Expanding Evidence-Based Options for Cannabis Use Disorder Treatment in Canada.

Jutras-Aswad D, Le Foll B, Bruneau J, Wild TC, Wood E, Fischer B.

Can J Psychiatry. 2019 Feb;64(2):82-87. doi: 10.1177/0706743718790955. Epub 2018 Jul 22. No abstract available.

25.

When and How to Treat Possible Cannabis Use Disorder.

Lévesque A, Le Foll B.

Med Clin North Am. 2018 Jul;102(4):667-681. doi: 10.1016/j.mcna.2018.02.009. Review.

PMID:
29933822
26.

Outcomes of an integrated care pathway for concurrent major depressive and alcohol use disorders: a multisite prospective cohort study.

Samokhvalov AV, Probst C, Awan S, George TP, Le Foll B, Voore P, Rehm J.

BMC Psychiatry. 2018 Jun 13;18(1):189. doi: 10.1186/s12888-018-1770-3.

27.

The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.

Socias ME, Ahamad K, Le Foll B, Lim R, Bruneau J, Fischer B, Wild TC, Wood E, Jutras-Aswad D.

Contemp Clin Trials. 2018 Jun;69:21-27. doi: 10.1016/j.cct.2018.04.001. Epub 2018 Apr 5.

28.

Psychosocial and pharmacological interventions for the treatment of cannabis use disorder.

Sabioni P, Le Foll B.

F1000Res. 2018 Feb 12;7:173. doi: 10.12688/f1000research.11191.1. eCollection 2018. Review.

29.

Alcohol Impairs N100 Response to Dorsolateral Prefrontal Cortex Stimulation.

Loheswaran G, Barr MS, Zomorrodi R, Rajji TK, Blumberger DM, Le Foll B, Daskalakis ZJ.

Sci Rep. 2018 Feb 21;8(1):3428. doi: 10.1038/s41598-018-21457-z.

30.

A method for co-creation of an evidence-based patient workbook to address alcohol use when quitting smoking in primary care: a case study.

Minian N, Noormohamed A, Zawertailo L, Baliunas D, Giesbrecht N, Le Foll B, Rehm J, Samokhvalov A, Selby PL.

Res Involv Engagem. 2018 Feb 5;4:4. doi: 10.1186/s40900-018-0086-2. eCollection 2018.

31.

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.

Trigo JM, Soliman A, Quilty LC, Fischer B, Rehm J, Selby P, Barnes AJ, Huestis MA, George TP, Streiner DL, Staios G, Le Foll B.

PLoS One. 2018 Jan 31;13(1):e0190768. doi: 10.1371/journal.pone.0190768. eCollection 2018.

32.

Influence of Nicotine Metabolism Ratio on [11C]-(+)-PHNO PET Binding in Tobacco Smokers.

Di Ciano P, Tyndale RF, Mansouri E, Hendershot CS, Wilson AA, Lagzdins D, Houle S, Boileau I, Le Foll B.

Int J Neuropsychopharmacol. 2018 Jun 1;21(6):503-512. doi: 10.1093/ijnp/pyx119.

33.

Improvement of the association between self-reported pill count and varenicline levels following exclusion of participants with misreported pill count: A commentary on Peng et al. (2017).

Peng AR, Le Foll B, Morales M, Lerman C, Schnoll R, Tyndale RF.

Addict Behav. 2018 Apr;79:14-16. doi: 10.1016/j.addbeh.2017.11.032. Epub 2017 Dec 2.

PMID:
29232593
34.

Deep TMS of the insula using the H-coil modulates dopamine release: a crossover [11C] PHNO-PET pilot trial in healthy humans.

Malik S, Jacobs M, Cho SS, Boileau I, Blumberger D, Heilig M, Wilson A, Daskalakis ZJ, Strafella AP, Zangen A, Le Foll B.

Brain Imaging Behav. 2018 Oct;12(5):1306-1317. doi: 10.1007/s11682-017-9800-1.

PMID:
29170944
35.

Effects of disulfiram on choice behavior in a rodent gambling task: association with catecholamine levels.

Di Ciano P, Manvich DF, Pushparaj A, Gappasov A, Hess EJ, Weinshenker D, Le Foll B.

Psychopharmacology (Berl). 2018 Jan;235(1):23-35. doi: 10.1007/s00213-017-4744-0. Epub 2017 Oct 30.

36.

Preliminary evaluation of a human laboratory model of impaired control over alcohol using intravenous alcohol self-administration.

Wardell JD, Le Foll B, Hendershot CS.

J Psychopharmacol. 2018 Jan;32(1):105-115. doi: 10.1177/0269881117723000. Epub 2017 Sep 11.

PMID:
28892421
37.

The effects of buspirone on occupancy of dopamine receptors and the rat gambling task.

Di Ciano P, Cormick PM, Stefan C, Wong E, Kim A, Remington G, Le Foll B.

Psychopharmacology (Berl). 2017 Nov;234(22):3309-3320. doi: 10.1007/s00213-017-4715-5. Epub 2017 Aug 19.

PMID:
28825117
38.

Management of mood and anxiety disorders in patients receiving opioid agonist therapy: Review and meta-analysis.

Hassan AN, Howe AS, Samokhvalov AV, Le Foll B, George TP.

Am J Addict. 2017 Sep;26(6):551-563. doi: 10.1111/ajad.12581. Epub 2017 Jul 4. Review.

PMID:
28675762
39.

Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations.

Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, Rehm J, Room R.

Am J Public Health. 2017 Aug;107(8):e1-e12. doi: 10.2105/AJPH.2017.303818. Epub 2017 Jun 23. Review. Erratum in: Am J Public Health. 2018 May;108(5):e2.

40.

Integrated care pathway for co-occurring major depressive and alcohol use disorders: Outcomes of the first two years.

Samokhvalov AV, Awan S, George TP, Irving J, Le Foll B, Perrotta S, Probst C, Voore P, Rehm J.

Am J Addict. 2017 Sep;26(6):602-609. doi: 10.1111/ajad.12572. Epub 2017 Jun 1.

PMID:
28570773
41.

The endocannabinoid system as a target for addiction treatment: Trials and tribulations.

Sloan ME, Gowin JL, Ramchandani VA, Hurd YL, Le Foll B.

Neuropharmacology. 2017 Sep 15;124:73-83. doi: 10.1016/j.neuropharm.2017.05.031. Epub 2017 May 28. Review.

PMID:
28564576
42.

Combining alcohol interventions with tobacco addictions treatment in primary care-the COMBAT study: a pragmatic cluster randomized trial.

Minian N, Baliunas D, Zawertailo L, Noormohamed A, Giesbrecht N, Hendershot CS, Le Foll B, Rehm J, Samokhvalov A, Selby PL.

Implement Sci. 2017 May 18;12(1):65. doi: 10.1186/s13012-017-0595-7.

43.

A Preliminary Investigation of the Effect of Acute Alcohol on Dopamine Transmission as Assessed by [11 C]-(+)-PHNO.

Thiruchselvam T, Wilson AA, Boileau I, Le Foll B.

Alcohol Clin Exp Res. 2017 Jun;41(6):1112-1119. doi: 10.1111/acer.13403. Epub 2017 May 29.

PMID:
28421623
44.

Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis.

Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B, Lintzeris N, Khor KE, Farrell M, Smith A, Le Foll B.

Neuropsychopharmacology. 2017 Aug;42(9):1752-1765. doi: 10.1038/npp.2017.51. Epub 2017 Mar 22. Review.

45.

Longitudinal alcohol consumption patterns and health-related quality of life: Results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Imtiaz S, Loheswaran G, Le Foll B, Rehm J.

Drug Alcohol Rev. 2018 Jan;37(1):48-55. doi: 10.1111/dar.12503. Epub 2017 Mar 14.

PMID:
28294429
46.

A 35-year-old woman with low mood and concerns about her alcohol use.

Samokhvalov AV, Le Foll B.

CMAJ. 2017 Feb 27;189(8):E317-E318. doi: 10.1503/cmaj.160132. No abstract available.

47.

Investigating the effects of norepinephrine α1 receptor blockade on dopamine levels: A pilot PET study with [11 C]-(+)-PHNO in controls.

Le Foll B, Thiruchselvam T, Lu SX, Mohammed S, Mansouri E, Lagzdins D, Nakajima S, Wilson AA, Graff-Guerrero A, Di Ciano P, Boileau I.

Synapse. 2017 Jul;71(7). doi: 10.1002/syn.21968. Epub 2017 Mar 17.

PMID:
28233334
48.

Corticotropin-releasing hormone and dopamine release in healthy individuals.

Payer D, Williams B, Mansouri E, Stevanovski S, Nakajima S, Le Foll B, Kish S, Houle S, Mizrahi R, George SR, George TP, Boileau I.

Psychoneuroendocrinology. 2017 Feb;76:192-196. doi: 10.1016/j.psyneuen.2016.11.034. Epub 2016 Dec 1.

PMID:
27951520
49.

A review of positron emission tomography studies exploring the dopaminergic system in substance use with a focus on tobacco as a co-variate.

Thiruchselvam T, Malik S, Le Foll B.

Am J Drug Alcohol Abuse. 2017 Mar;43(2):197-214. doi: 10.1080/00952990.2016.1257633. Epub 2016 Nov 30. Review.

50.

Effects of varenicline on motor cortical plasticity in non-smokers with schizophrenia.

Bridgman AC, Barr MS, Goodman MS, Zomorrodi R, Rajji T, Le Foll B, Chen R, Daskalakis ZJ, George TP.

Schizophr Res. 2016 Dec;178(1-3):50-55. doi: 10.1016/j.schres.2016.08.031. Epub 2016 Sep 6.

PMID:
27613505

Supplemental Content

Loading ...
Support Center